NO20081816L - Farmasoytiske sammensetninger inneholdende pregabalin - Google Patents

Farmasoytiske sammensetninger inneholdende pregabalin

Info

Publication number: NO20081816L
Authority: NO; Norway
Prior art keywords: pharmaceutical compositions; compositions containing; containing pregabalin; polyvinylpyrrolidone; agents include
Prior art date: 2005-11-02

Application number

NO20081816A

Other languages

English (en)

Norwegian (no)

Inventor

Howard Norman Bockbrader

Yun Hyung Cho

Steven Diaz Santiago

Majid Mahjour

Thomas Daniel Reynolds

Pushpa Ganapathi Shao

Zezhi Jesse Shao

Jiansheng Wan

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-11-02

Filing date

2008-04-14

Publication date

2008-05-08

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37965070&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20081816(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-04-14 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2008-05-08 Publication of NO20081816L publication Critical patent/NO20081816L/no

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Inorganic Chemistry (AREA)
Addiction (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Anesthesiology (AREA)
Rheumatology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO20081816A 2005-11-02 2008-04-14 Farmasoytiske sammensetninger inneholdende pregabalin NO20081816L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US73258905P	2005-11-02	2005-11-02
PCT/IB2006/003063 WO2007052125A2 (fr)	2005-11-02	2006-10-23	Compositions pharmaceutiques solides contenant de la pregabaline

Publications (1)

Publication Number	Publication Date
NO20081816L true NO20081816L (no)	2008-05-08

Family

ID=37965070

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20081816A NO20081816L (no)	2005-11-02	2008-04-14	Farmasoytiske sammensetninger inneholdende pregabalin

Country Status (33)

Country	Link
US (11)	US20070269511A1 (fr)
EP (1)	EP1945186B1 (fr)
JP (1)	JP4334610B2 (fr)
KR (1)	KR101012533B1 (fr)
CN (1)	CN101330907B (fr)
AP (1)	AP2008004465A0 (fr)
AR (1)	AR058175A1 (fr)
AU (1)	AU2006310217B2 (fr)
BR (1)	BRPI0618211B8 (fr)
CA (1)	CA2628200C (fr)
CR (1)	CR9950A (fr)
DK (1)	DK1945186T3 (fr)
DO (1)	DOP2006000241A (fr)
EA (1)	EA012377B1 (fr)
EC (1)	ECSP088422A (fr)
ES (1)	ES2449231T3 (fr)
GT (1)	GT200600474A (fr)
IL (1)	IL190827A (fr)
MA (1)	MA30135B1 (fr)
ME (1)	ME00482B (fr)
NL (1)	NL2000281C2 (fr)
NO (1)	NO20081816L (fr)
NZ (1)	NZ567414A (fr)
PE (1)	PE20070693A1 (fr)
PL (1)	PL1945186T3 (fr)
PT (1)	PT1945186E (fr)
RS (1)	RS20080181A (fr)
SI (1)	SI1945186T1 (fr)
TN (1)	TNSN08194A1 (fr)
TW (1)	TWI330080B (fr)
UY (1)	UY29890A1 (fr)
WO (1)	WO2007052125A2 (fr)
ZA (1)	ZA200803115B (fr)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU714980B2 (en)	1996-07-24	2000-01-13	Warner-Lambert Company Llc	Isobutylgaba and its derivatives for the treatment of pain
ES2380010T3 (es) *	2007-10-16	2012-05-07	Pharmathen S.A.	Composición farmacéutica mejorada que contiene un anticonvulsivante derivado de la pirrolidona y método para su preparación
EP2242737A1 (fr) *	2007-12-21	2010-10-27	Synthon B.V.	Sels de prégabaline
MY150971A (en) *	2008-07-09	2014-03-31	Melaleuca Inc	Mineral amino acid polysaccharide complex
AU2010258345A1 (en) *	2009-06-12	2012-01-19	Micro Labs Limited	Novel pharmaceutical compositions containing pregabalin
WO2010150221A1 (fr)	2009-06-25	2010-12-29	Wockhardt Research Centre	Compositions pharmaceutiques de prégabaline de saveur masquée
KR101317592B1 (ko) *	2009-10-28	2013-10-15	씨제이제일제당 (주)	프레가발린, 폴리에틸렌옥사이드 및 폴리비닐알코올-폴리에틸렌글리콜 그라프트 공중합체를 함유하는 위체류형 서방성 제제
NZ601450A (en) *	2010-02-24	2014-09-26	Zoetis Llc	Veterinary compositions
HU230031B1 (hu) *	2010-03-01	2015-05-28	Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság	Pregabalint és izomaltot tartalmazó stabilizált gyógyszerkészítmény
MX336038B (es) *	2010-04-07	2016-01-07	Lupin Ltd	Composiciones farmaceuticas de liberacion controlada de tapentadol.
EP2389933A1 (fr)	2010-05-25	2011-11-30	Sanovel Ilac Sanayi ve Ticaret A.S.	Compositions comprenant de la prégabaline à libération contrôlée
TR201005241A1 (tr)	2010-05-25	2012-01-23	Sanovel �La� San. Ve T�C. A.�.	Kontrollü salım sağlayan pregabalin solüsyon formülasyonu.
EP2389934A1 (fr)	2010-05-25	2011-11-30	Sanovel Ilac Sanayi ve Ticaret A.S.	Formulations de prégabaline en comprimé à libération prolongée
WO2011151708A1 (fr)	2010-06-01	2011-12-08	Rubicon Research Private Limited	Formes posologiques à rétention gastrique d'analogues de gaba
CA2801620A1 (fr)	2010-07-06	2012-01-12	Gruenenthal Gmbh	Nouvelles formes posologiques a retention gastrique comprenant un analogue de gaba et un opioide
EP2415460A1 (fr) *	2010-08-03	2012-02-08	ratiopharm GmbH	Formulations pour l'administration orale de prégabaline
WO2012035559A2 (fr) *	2010-09-17	2012-03-22	Panacea Biotec Ltd	Compositions pharmaceutiques à libération prolongée contenant de la prégabaline
JP6027539B2 (ja)	2010-12-02	2016-11-16	ウーツェーベーファルマゲーエムベーハーＵｃｂＰｈａｒｍａＧｍｂｈ	ラコサミドの１日１回投与用製剤
EA017542B1 (ru) *	2011-05-24	2013-01-30	Плива Кроэйша Лтд.	Стабильная фармацевтическая композиция, содержащая прегабалин, капсула, ее содержащая, способ получения и применение
KR101724024B1 (ko) *	2011-07-26	2017-04-06	주식회사유한양행	2상 방출-제어 시스템에 의한 프레가발린을 함유하는 서방성 정제
CN102908327B (zh) *	2011-08-05	2015-03-11	江苏恒瑞医药股份有限公司	伊伐布雷定或其可药用盐的缓释制剂
KR101438546B1 (ko) *	2011-08-26	2014-09-17	근화제약주식회사	프레가발린을 포함하는 서방성 제제
EP2809304A1 (fr)	2012-01-30	2014-12-10	Ranbaxy Laboratories Limited	Comprimés gastro-résistants
WO2013114281A1 (fr)	2012-01-30	2013-08-08	Ranbaxy Laboratories Limited	Comprimés de prégabaline gastro-résistants
CN102743357A (zh) *	2012-06-26	2012-10-24	严轶东	一种普瑞巴林胃内泡腾漂浮缓释制剂及其制备方法
EP2908803A1 (fr)	2012-10-16	2015-08-26	Ranbaxy Laboratories Limited	Comprimés osmotiques flottants
WO2015114655A2 (fr) *	2014-01-21	2015-08-06	Intas Pharmaceuticals Limited	Comprimé de prégabaline à libération modifiée
WO2015114509A1 (fr)	2014-01-28	2015-08-06	Ranbaxy Laboratories Limited	Comprimés à rétention gastrique stabilisée de prégabaline
KR102221846B1 (ko) *	2014-04-07	2021-02-26	영진약품 주식회사	안정성이 개선된 프레가발린을 함유하는 약제학적 조성물 및 이의 제조방법
CN111840239B (zh) *	2014-10-24	2022-11-18	江苏恒瑞医药股份有限公司	一种普瑞巴林缓释制剂
CN104906064B (zh) *	2015-05-15	2017-12-22	中国药科大学	一种普瑞巴林胃漂浮缓释片剂及其制备方法
US9747110B2 (en) *	2015-05-20	2017-08-29	Altera Corporation	Pipelined cascaded digital signal processing structures and methods
WO2016187718A1 (fr) *	2015-05-26	2016-12-01	Isa Odidi	Prégabaline à libération prolongée contrôlée
CN104840443B (zh) *	2015-05-27	2018-04-27	齐鲁制药有限公司	含活性成分普瑞巴林的药物组合物
WO2017058869A1 (fr)	2015-09-29	2017-04-06	Acorda Therapeutics, Inc.	Compositions à libération prolongée de 4-aminopyridine
EP3484456A4 (fr)	2016-07-17	2020-03-18	Mapi Pharma Limited	Formes galéniques à libération prolongée de prégabaline
JP6919119B2 (ja) *	2017-01-23	2021-08-18	日新製薬株式会社	３位が置換されたγ−アミノ酪酸誘導体を含有する圧縮固形医薬組成物。
JP2019142834A (ja) *	2017-07-31	2019-08-29	大原薬品工業株式会社	プレガバリン並びに好適な賦形剤を含有する固形製剤
JP7138666B2 (ja) *	2018-01-24	2022-09-16	大原薬品工業株式会社	γ－アミノ酪酸誘導体含有錠剤の化学的安定性を改善する方法
EP3542862A1 (fr) *	2018-03-22	2019-09-25	Nitto Denko Corporation	Procédé de production d'une composition contenant de la prégabaline et composition contenant de la prégabaline
US11938222B2 (en)	2018-06-13	2024-03-26	Beijing Tide Pharmaceutical Co., Ltd.	Pregabalin sustained release composition and method for preparing the same
CN110585153A (zh) *	2018-06-13	2019-12-20	北京泰德制药股份有限公司	一种普瑞巴林缓释组合物及其制备方法
CN111053749B (zh) *	2018-10-16	2022-07-15	北京泰德制药股份有限公司	一种普瑞巴林缓释组合物及其制备方法
CA3105212A1 (fr) *	2018-06-28	2020-01-02	Mylan Inc.	Formulations a liberation prolongee de pregabaline
CN109044981B (zh) *	2018-08-07	2021-02-19	广州帝奇医药技术有限公司	一种普瑞巴林胃漂浮型缓释片及其制备方法
RS64394B1 (sr)	2019-07-03	2023-08-31	Alvogen Inc	Tablete pregabalina sa kontrolisanim otpuštanjem, postupak njihove proizvodnje i način upotrebe
US12012413B2 (en) *	2019-11-11	2024-06-18	Tenacia Biotechnology (Hong Kong) Co., Limited	Methods of treating painful diabetic peripheral neuropathy
CN110974798A (zh) *	2019-12-19	2020-04-10	江苏优仿医药科技有限公司	药物组合物、缓释片剂及其制备方法
TW202214223A (zh) *	2020-07-20	2022-04-16	大陸商四川海思科製藥有限公司	稠合三環γ-胺基酸衍生物的緩釋藥物製劑及其製備方法
EP4309648A4 (fr) *	2021-03-17	2025-03-05	Shanghai Yonsun Biotechnology Co., Ltd.	Composition pharmaceutique de lacosamide, son procédé de préparation et ses applications
CN113577036B (zh) *	2021-05-31	2023-04-04	石药集团欧意药业有限公司	一种普瑞巴林胃漂浮缓释片及其制备方法
GB2624861A (en) *	2022-11-28	2024-06-05	Orbit Pharma Ltd	Sustained release pharmaceutical compositions comprising pregabalin or pharmaceutically acceptable salts thereof
GB2639602A (en)	2024-03-19	2025-10-01	Novumgen Ltd	An orodispersible tablet of pregabalin and its process of preparation
CN120324357B (zh) *	2025-06-03	2025-10-24	上海国创医药股份有限公司	一种普瑞巴林缓释组合物及其制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE59145T1 (de)	1983-05-02	1991-01-15	Diamond Scient Co	Photochemische entkeimungsbehandlung von vollem blut oder blutbestandteilen.
DE3928183A1 (de)	1989-08-25	1991-02-28	Goedecke Ag	Lactamfreie cyclische aminosaeuren
US6197819B1 (en) *	1990-11-27	2001-03-06	Northwestern University	Gamma amino butyric acid analogs and optical isomers
US5616793A (en) *	1995-06-02	1997-04-01	Warner-Lambert Company	Methods of making (S)-3-(aminomethyl)-5-methylhexanoic acid
US5637767A (en) *	1995-06-07	1997-06-10	Warner-Lambert Company	Method of making (S)-3-(aminomethyl)-5-methylhexanoic acid
IT1282650B1 (it)	1996-02-19	1998-03-31	Jagotec Ag	Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
US6271278B1 (en)	1997-05-13	2001-08-07	Purdue Research Foundation	Hydrogel composites and superporous hydrogel composites having fast swelling, high mechanical strength, and superabsorbent properties
PT1003476E (pt)	1997-08-11	2005-05-31	Alza Corp	Forma de dosagem de agente activo de libertacao prolongada adaptada para retencao gastrica
IN186245B (fr) *	1997-09-19	2001-07-14	Ranbaxy Lab Ltd
BR9910494B1 (pt)	1998-05-15	2011-11-01		composições sólidas contendo derivados de ácido gama-aminobutìrico e processo para o seu preparo.
IL139298A0 (en)	1998-05-15	2001-11-25	Warner Lambert Co	Stabilized pharmaceutical preparations of gamma-aminobutyric acid derivatives and process for preparing the same
EP1250311B1 (fr) *	2000-01-27	2004-03-17	Warner-Lambert Company	Synthese asymetrique de pregabaline
DE10014588A1 (de) *	2000-03-27	2001-10-04	Basf Ag	Wirkstoffhaltige Schwimmformen enthaltend Polyvinylacetat und Polyvinylpyrrolidon, deren Verwendung und Herstellung
DE60101476T2 (de)	2000-06-16	2004-05-27	Teva Pharmaceutical Industries Ltd.	Stabiles gabapentin, das mehr als 20 ppm chlor enthält
US6488962B1 (en)	2000-06-20	2002-12-03	Depomed, Inc.	Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
AU6872201A (en)	2000-06-23	2002-01-08	Teva Pharma	Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
CA2356829A1 (fr) *	2000-09-22	2002-03-22	Warner-Lambert Company	Methode de traitement de l'asthme avec la pregabaline
US7056951B2 (en)	2000-09-26	2006-06-06	Mutual Pharmaceutical Co., Inc.	Stable solid dosage forms of amino acids and processes for producing same
TWI312285B (en)	2001-10-25	2009-07-21	Depomed Inc	Methods of treatment using a gastric retained gabapentin dosage
US6723340B2 (en)	2001-10-25	2004-04-20	Depomed, Inc.	Optimal polymer mixtures for gastric retentive tablets
EP1670451A4 (fr) *	2003-09-11	2009-10-21	Xenoport Inc	Traitement et/ou prevention de l'incontinence urinaire et promedicaments des analogues gaba
AU2004285532A1 (en)	2003-10-31	2005-05-12	Alza Corporation	Administration of levodopa and carbidopa

2006
- 2006-10-17 NL NL2000281A patent/NL2000281C2/nl not_active IP Right Cessation
- 2006-10-23 JP JP2008538441A patent/JP4334610B2/ja active Active
- 2006-10-23 AP AP2008004465A patent/AP2008004465A0/xx unknown
- 2006-10-23 KR KR1020087010794A patent/KR101012533B1/ko active Active
- 2006-10-23 PT PT68091545T patent/PT1945186E/pt unknown
- 2006-10-23 EP EP06809154.5A patent/EP1945186B1/fr active Active
- 2006-10-23 WO PCT/IB2006/003063 patent/WO2007052125A2/fr not_active Ceased
- 2006-10-23 SI SI200631740T patent/SI1945186T1/sl unknown
- 2006-10-23 AU AU2006310217A patent/AU2006310217B2/en active Active
- 2006-10-23 CA CA2628200A patent/CA2628200C/fr not_active Expired - Fee Related
- 2006-10-23 EA EA200800931A patent/EA012377B1/ru not_active IP Right Cessation
- 2006-10-23 ME MEP-2008-761A patent/ME00482B/fr unknown
- 2006-10-23 DK DK06809154.5T patent/DK1945186T3/en active
- 2006-10-23 PL PL06809154T patent/PL1945186T3/pl unknown
- 2006-10-23 NZ NZ567414A patent/NZ567414A/en unknown
- 2006-10-23 ES ES06809154.5T patent/ES2449231T3/es active Active
- 2006-10-23 BR BRPI0618211A patent/BRPI0618211B8/pt active IP Right Grant
- 2006-10-23 CN CN2006800411407A patent/CN101330907B/zh active Active
- 2006-10-23 RS RSP-2008/0181A patent/RS20080181A/sr unknown
- 2006-10-30 PE PE2006001329A patent/PE20070693A1/es not_active Application Discontinuation
- 2006-10-31 UY UY29890A patent/UY29890A1/es not_active Application Discontinuation
- 2006-10-31 GT GT200600474A patent/GT200600474A/es unknown
- 2006-10-31 AR ARP060104778A patent/AR058175A1/es not_active Application Discontinuation
- 2006-11-01 DO DO2006000241A patent/DOP2006000241A/es unknown
- 2006-11-01 TW TW095140374A patent/TWI330080B/zh active
- 2006-11-02 US US11/555,988 patent/US20070269511A1/en not_active Abandoned
2008
- 2008-04-09 ZA ZA200803115A patent/ZA200803115B/xx unknown
- 2008-04-13 IL IL190827A patent/IL190827A/en active IP Right Grant
- 2008-04-14 NO NO20081816A patent/NO20081816L/no not_active Application Discontinuation
- 2008-04-30 EC EC2008008422A patent/ECSP088422A/es unknown
- 2008-04-30 TN TNP2008000194A patent/TNSN08194A1/fr unknown
- 2008-05-02 CR CR9950A patent/CR9950A/es not_active Application Discontinuation
- 2008-05-02 MA MA30892A patent/MA30135B1/fr unknown
2011
- 2011-10-06 US US13/267,352 patent/US20120029081A1/en not_active Abandoned
2012
- 2012-05-16 US US13/472,704 patent/US20120232149A1/en not_active Abandoned
- 2012-12-06 US US13/706,971 patent/US20130102675A1/en not_active Abandoned
2013
- 2013-07-22 US US13/947,433 patent/US20130303618A1/en not_active Abandoned
2014
- 2014-02-17 US US14/181,785 patent/US8945620B2/en active Active
- 2014-12-15 US US14/570,115 patent/US9144559B2/en active Active
2015
- 2015-08-20 US US14/831,205 patent/US20150352066A1/en not_active Abandoned
2016
- 2016-03-18 US US15/074,042 patent/US20160250147A1/en not_active Abandoned
2017
- 2017-01-30 US US15/418,907 patent/US20170136125A1/en not_active Abandoned
- 2017-08-25 US US15/686,549 patent/US10022447B2/en active Active

Also Published As

Publication number	Publication date
BRPI0618211B8 (pt)	2021-05-25
US20160250147A1 (en)	2016-09-01
US20120232149A1 (en)	2012-09-13
IL190827A (en)	2012-08-30
AR058175A1 (es)	2008-01-23
IL190827A0 (en)	2008-12-29
ZA200803115B (en)	2009-09-30
US20170348420A1 (en)	2017-12-07
CN101330907B (zh)	2012-08-29
MA30135B1 (fr)	2009-01-02
US20130303618A1 (en)	2013-11-14
CN101330907A (zh)	2008-12-24
EP1945186A2 (fr)	2008-07-23
ECSP088422A (es)	2008-05-30
AP2008004465A0 (en)	2008-06-30
TWI330080B (en)	2010-09-11
EA012377B1 (ru)	2009-10-30
EA200800931A1 (ru)	2008-10-30
US20170136125A1 (en)	2017-05-18
CA2628200C (fr)	2011-01-25
NL2000281A1 (nl)	2007-05-03
CR9950A (es)	2008-05-28
PE20070693A1 (es)	2007-08-11
BRPI0618211A2 (pt)	2011-08-23
TNSN08194A1 (fr)	2009-10-30
US8945620B2 (en)	2015-02-03
AU2006310217B2 (en)	2012-08-16
RS20080181A (sr)	2009-07-15
JP2009514847A (ja)	2009-04-09
KR20080059427A (ko)	2008-06-27
BRPI0618211B1 (pt)	2020-11-17
US20150352066A1 (en)	2015-12-10
PT1945186E (pt)	2014-03-06
US20130102675A1 (en)	2013-04-25
TW200803831A (en)	2008-01-16
US20140163103A1 (en)	2014-06-12
ES2449231T3 (es)	2014-03-18
US20150094371A1 (en)	2015-04-02
UY29890A1 (es)	2007-05-31
WO2007052125A2 (fr)	2007-05-10
US20070269511A1 (en)	2007-11-22
PL1945186T3 (pl)	2014-05-30
US9144559B2 (en)	2015-09-29
HK1126394A1 (en)	2009-09-04
AU2006310217A1 (en)	2007-05-10
WO2007052125A3 (fr)	2007-09-07
DK1945186T3 (en)	2014-03-17
KR101012533B1 (ko)	2011-02-07
SI1945186T1 (sl)	2014-03-31
EP1945186B1 (fr)	2014-01-22
GT200600474A (es)	2007-06-08
US20120029081A1 (en)	2012-02-02
JP4334610B2 (ja)	2009-09-30
DOP2006000241A (es)	2007-05-31
NL2000281C2 (nl)	2007-08-07
NZ567414A (en)	2011-09-30
ME00482B (fr)	2011-10-10
US10022447B2 (en)	2018-07-17
CA2628200A1 (fr)	2007-05-10

Publication	Publication Date	Title
NO20081816L (no)	2008-05-08	Farmasoytiske sammensetninger inneholdende pregabalin
NO20011471D0 (no)	2001-03-22	Nye orale vedvarende frigivelsesformuleringer
NO20016108D0 (no)	2001-12-14	Kontrollert frigivelse og smaks maskerende orale farmasöytiske sammensetninger
MXPA06000407A (es)	2006-03-17	Isomero c cci-779.
BR0312347A (pt)	2005-04-12	Composição farmacêutica oral, usos da espessura de revestimento de um material de revestimento dependente do ph de dissolução, de um material de revestimento, e de um material de polimetacrilato
BR0306870A (pt)	2004-11-03	Composição farmacêutica oral, e, método para preparar a mesma
MX2008000099A (es)	2008-03-19	Composiciones farmaceuticas de liberacion modificada novedosas, y procedimiento de preparacion de dichas composiciones.
MX2009003516A (es)	2009-04-14	Formas de dosificacion solidas farmaceuticas que comprenden compuestos microincluidos en polimeros ionicos insolubles en agua.
NO20073405L (no)	2007-07-02	Farmasoytisk utforming inneholdende en frigjoringshastighetskontrollerende sammensetning
DE602004011398D1 (de)	2008-03-06	Direkt komprimierbare pharmazeutische zusammensetzung für die orale verabreichung von cci-779
DK1185253T3 (da)	2004-04-05	Oralt præparat til indgivelse af en fast kombination af tramadol og diclofenac
EA200901393A1 (ru)	2010-02-26	Фармацевтическая композиция, содержащая гестагены и/или эстрогены и 5 метил-(6s)-тетрагидрофолат
DE602004005564D1 (de)	2007-05-10	Pharmazeutische Zusammensetzung für Thrombinpeptidderivaten
NO20052683D0 (no)	2005-06-03	Nye pyridopyrimidinonforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
AU2003230189A1 (en)	2004-08-23	Oral controlled release pharmaceutical composition containing metaxalone as active agent
NO304113B1 (no)	1998-10-26	Krystallinsk tiagabinhydrokloridmonohydrat, farmas°ytisk preparat som omfatter det, og anvendelse derav for fremstilling av et medikament
WO2007143163A3 (fr)	2008-07-24	Compositions pharmaceutiques pour la libération prolongée de phenylephrine
ES2305567T3 (es)	2008-11-01	Formulaciones de tramadol de liberacion sostenida con una eficacia de 24 horas.
ATE503749T1 (de)	2011-04-15	Buttersäurederivate, verfahren zu deren herstellung, pharmazeutische zusammensetzungen, die diese enthalten, und therapeutische anwendungen davon
CR8748A (es)	2008-06-02	Una composicion farmaceutica antimicobacteriana
DE602004022515D1 (de)	2009-09-24	Fenofibrate tablett und verfahren zur herstellung
TR200601092T1 (tr)	2006-08-21	İrbesartan etkin maddesi içeren yeni oral farmasötik formülasyonlar.
DK1537132T3 (da)	2006-05-08	Salt af mortin-6-glucuronid
EA200601015A1 (ru)	2006-10-27	Пероральные композиции дезоксипеганина и их применение
CY1115009T1 (el)	2016-12-14	Στερεες απο του στοματος φαρμακευτικες συνθεσεις για δοσολογηση μιας φορας ημερησιως που περιεχουν πρεγκαμπαλινη, παραγοντα σχηματισμου μητρας και παραγοντα διογκωσης

Legal Events

Date	Code	Title	Description
2010-05-31	FC2A	Withdrawal, rejection or dismissal of laid open patent application